

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 June 2024 (27.06.2024)



(10) International Publication Number
WO 2024/138190 A8

(51) International Patent Classification:

C07D 401/04 (2006.01) A61K 31/4439 (2006.01)
A61P 11/00 (2006.01)

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(21) International Application Number:

PCT/US2023/085811

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(22) International Filing Date:

22 December 2023 (22.12.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/477,000 23 December 2022 (23.12.2022) US

Published:

— with international search report (Art. 21(3))

(71) Applicant: BRISTOL-MYERS SQUIBB COMPANY
[US/US]; Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US).

(48) Date of publication of this corrected version:

06 September 2024 (06.09.2024)

(72) Inventor: TAO, Shiwei; c/o Bristol-Myers Squibb Compa-
ny, Route 206 and Province Line Road, Princeton, New Jer-
sey 08543 (US).


(15) Information about Correction:

see Notice of 06 September 2024 (06.09.2024)

(74) Agent: CALVO, Paul A. et al.; Sterne, Kessler, Goldstein
& Fox P.L.L.C., 1101 K Street, NW, 10th Floor, Washing-
ton, District of Columbia 20005 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: CRYSTALLINE FORMS OF A LPA₁ ANTAGONIST



(57) Abstract: Described herein is the LPA₁ antagonist (1S,3S)-3-((2-methyl-6-((1-methyl-5-(((methyl(propyl)carbamoyl)oxy)methyl)-1H-1,2,3-triazol-4-yl)pyridin-3-yl)oxy)cyclohexane-1-carboxylic acid, including crystalline forms of Compound (A) and preparations thereof. Also disclosed are pharmaceutical compositions that include the LPA₁ antagonist, methods of using the LPA₁ antagonist for the treatment of interstitial lung disease.